
Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.
Eterna Therapeutics is a biotechnology company focused on unlocking the power of cell engineering for curative and transformative therapies. The company leverages its robust intellectual property portfolio to develop and out-license technology platforms aimed at providing new medicines for patients with cancer and immunologic diseases. Eterna's approach explores the potential of the human immune system in treatment, both as a standalone therapy and in combination with other approaches.
The company's mission is to redefine possibilities in cellular and gene therapy, with a current focus on co-developing and out-licensing its proprietary technology platforms. Eterna Therapeutics aims to deliver transformational new medicines to patients, positioning itself at the forefront of innovative cell engineering solutions for complex diseases.

Cell BioEngines
cellbioengines.com

Cellular Approaches

Mana Therapeutics

Cartesian Therapeutics

Thymmune Therapeutics
thymmune.com

CERo Therapeutics
cero.bio

Century Therapeutics
centurytx.com

LTZ Therapeutics

Aleta Biotherapeutics
aletabio.com

Kyverna Therapeutics

Vita Therapeutics

HebeCell
hebecellcorp.com

Seneca Therapeutics

Immunitas Therapeutics
immunitastx.com

Modulus Therapeutics
Companies similar to Ernexa Therapeutics include Cell BioEngines, Cellular Approaches, Mana Therapeutics and Cartesian Therapeutics.
Ernexa Therapeutics was founded in 1984.
Ernexa Therapeutics' headquarters is located in Cambridge, MA, US.
Ernexa Therapeutics' most recent funding round was for $9.2M (USD) in December 2023.
As of Dec 14, 2023, Ernexa Therapeutics has raised a total of $49.1M (USD).
Ernexa Therapeutics has 11 employees as of Feb 5, 2024.